PV Bulletin
PvBulletin
Home /Regulators/Nature's Own Glucosamine Sulfate with Chondroitin and Nature's Own Magnesium Glycinate 1150mg Recall by Sanofi Consumer Healthcare
RegulatorsTherapeutic Goods Administration (TGA)Australia

Nature's Own Glucosamine Sulfate with Chondroitin and Nature's Own Magnesium Glycinate 1150mg Recall by Sanofi Consumer Healthcare

Sanofi Consumer Healthcare recalls Nature's Own Glucosamine Sulfate with Chondroitin (320 pack) and Nature's Own Magnesium Glycinate 1150mg (300 pack) due to potential presence of glass fragments in the bottle.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Action needed

Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

Owner

Regulatory Intelligence Lead

Review cadence

one-time

Regulatory action details

Action type
Recall
Publication date
2026-06-03
Safety issue
Sanofi Consumer Healthcare is recalling the products due to the potential presence of a glass fragment within the bottle (not within the tablets). There is a risk of users being cut when handling the product, and it could also be harmful if accidentally swallowed.

Affected products

  • Nature’s Own Glucosamine Sulfate with Chondroitin (320 pack)
    Sanofi Consumer Healthcare
    1662937
  • Nature’s Own Magnesium Glycinate 1150mg (300 pack)
    Sanofi Consumer Healthcare
    1665576

PV internal implications

Return the product to the place of purchase for a refund, or contact Customer Care to arrange return and a refund.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 3, 2026

Full briefing

What changed

Recall initiated for Nature's Own Glucosamine Sulfate with Chondroitin (batch 1662937) and Nature's Own Magnesium Glycinate 1150mg (batch 1665576) due to glass fragments.

Why it matters

Glass fragments can cause injury when handling product or harm if accidentally swallowed, requiring immediate consumer action.

Practical implication

Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

#Safety Signals#Recalls#Recall#Therapeutic Goods Administration (TGA)#safety_signal#firecrawl-agent#regulatory-extraction

Related updates for your role

RegulatorsHealth CanadaCanada

Dexcom G7 Sensor Lot Recall – Unauthorized Distribution of Non-Conforming Lots in Canada

Regulatory action
Health product recall
Dexcom G7 Sensor 1 Pack · Dexcom, Inc.
Lot/batch: 1725204004, 1725069002
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify and quarantine products from lots 1725204004 and 1725069002; contact patients who received sensors from these lots; report adverse events if any.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Class 2 Recall: ChloraPrep 2% applicators (potential sterility breach)

Regulatory action
Class 2 Medicines Recall
ChloraPrep 2% 1mL applicator · Becton Dickinson UK Ltd
Lot/batch: All lots with an expiry date up to and including 02/2028. For a full list, see Annex 1.
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify and quarantine all impacted batches of ChloraPrep 2% 1mL and Frepp 2% 1.5mL applicators; return to Becton Dickinson UK Ltd.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsHealth CanadaCanada

Omnipod Insulin Management System Recall in Canada

Regulatory action
Health product recall
Omnipod Insulin Management System · Insulet Corporation
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify affected lots and implement recall procedures as per Health Canada guidelines.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
Nature's Own Glucosamine Sulfate with Chondroitin and Nature's Own Magnesium Glycinate 1150mg Recall by Sanofi Consumer Healthcare | PV Bulletin